home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Arsenal Files 6
/
The Arsenal Files 6 (Arsenal Computer).ISO
/
health
/
med9603.zip
/
M9630560.TXT
< prev
next >
Wrap
Text File
|
1996-02-27
|
2KB
|
28 lines
Document 0560
DOCN M9630560
TI Working toward a common currency: is standardization of
cost-effectiveness analysis possible?
DT 9603
AU Luce BR; MEDTAP International, Inc., Arlington, Virginia 22201, USA.
SO J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 4:S19-22.
Unique Identifier : AIDSLINE MED/96075585
AB The field of cost-effectiveness has been quietly evolving for several
decades. However, concerns and controversies have recently surfaced
regarding the lack of standardization with which cost-effectiveness
analyses are performed. This attention is due to the increasing use of
the technique in rationing health care, setting price and/or
reimbursement levels, adopting new technologies, and marketing
pharmaceutical products. Is standardization possible while the field is
still developing? This article explores possible answers to this
question and reviews worldwide efforts aimed at the development of
standardized guidelines for cost-effectiveness analysis.
DE Acquired Immunodeficiency Syndrome/DRUG THERAPY/ECONOMICS Antiviral
Agents/ECONOMICS Clinical Trials Cost-Benefit Analysis/*STANDARDS
Economics, Pharmaceutical/STANDARDS Guidelines Human Models,
Theoretical Prospective Studies Quality of Life Research Design
Retrospective Studies JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).